Circulating tumor DNA predicts the outcome of chemotherapy in patients with lung cancer
Open Access
- 18 November 2021
- journal article
- research article
- Published by Wiley in Thoracic Cancer
- Vol. 13 (1) , 95-106
Abstract
Background: Circulating tumor DNA (ctDNA) has potential as a specific, noninvasive, and cost‐effective new biomarker for patients with lung cancer. This study aimed to determine whether plasma ctDNA can be used to predict treatment outcomes in patients with lung cancer.Methods: Pre‐ and in‐treatment blood samples were collected from 14 patients with lung cancer receiving chemotherapy. Based on next‐generation sequencing technology, we constructed a unique molecular identifier (UMI) library and performed targeted deep sequencing of 72 genes (15 000×). We used dVAF to evaluate the change level and trend of variant allele frequency (VAF).Results: We identified MUC16, KMT2D, AMER1, and NTRK1 as the most‐frequently mutated genes in ctDNA associated with lung cancer. Furthermore, we showed that the change trend of dVAF in patients with lung cancer undergoing chemotherapy was closely related to the changes in both tumor volume and tumor biomarkers, including CEA, CA125, NSE, and CK (Cytokeratin). Moreover, the ctDNA analysis revealed disease progression of SCLC patients earlier than did computed tomography.Conclusions: The dynamic detection of plasma ctDNA VAF has the potential value as a biomarker for evaluating the efficacy of chemotherapy in patients with SCLC and advanced NSCLC, and may predict the progression of lung cancer patients earlier than radiography.Keywords
This publication has 25 references indexed in Scilit:
- Circulating Tumor Cells and DNA for Real-Time EGFR Detection and Monitoring of Non-Small-Cell Lung CancerFuture Oncology, 2017
- Non-small cell lung cancer: current treatment and future advancesTranslational Lung Cancer Research, 2016
- Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- EGFR mutations in lung cancer: from tissue testing to liquid biopsyFuture Oncology, 2015
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)Lung Cancer, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?Journal of Clinical Oncology, 2013
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast CancerNew England Journal of Medicine, 2003
- Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trialThe Lancet, 2003